TG Therapeutics, Inc. (NASDAQ: TGTX) shares gave back 1.2% to $4.94, as the company announced the completion of enrollment into Part 1 of its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Share volume came in at 374,000 compared to an all-day average of 560,000
